article thumbnail

Streamlining Compliance in the Pharmaceutical Industry with the eQMS

Dot Compliance

In the pharmaceutical industry, the importance of regulatory compliance extends beyond fulfilling legal obligations. Compliance can be streamlined with the help of an electronic quality management system (eQMS) that incorporates regulatory standards into every operational aspect of a pharmaceutical organization.

article thumbnail

Opill’s FDA Approval: Implications for Pharmaceutical Regulation and Access to Care

Bill of Health

By James René Jolin and Susannah Baruch On July 13, 2023, the United States Food and Drug Administration (FDA) approved Opill (norgestrel) as the first daily oral contraceptive available for non-prescription use in the U.S. James René Jolin (JRJ): This recent move by the FDA is one without precedent. It was a long time coming.

FDA 184
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating FDA Compliance: A Guide to 21 CFR Part 210 and Part 211

Dot Compliance

In the pharmaceutical industry, ensuring the safety and quality of drugs is paramount. Food and Drug Administration (FDA) to meet the Current Good Manufacturing Practice (cGMP) standards. The post Navigating FDA Compliance: A Guide to 21 CFR Part 210 and Part 211 appeared first on Dot Compliance.

FDA 52
article thumbnail

Ketamine is the New Viagra

Bill of Health

By Vincent Joralemon Spravato, the first FDA-approved psychedelic therapy, just outsold Viagra. Remarkably, a therapeutic made from ketamine, once dismissed as a “club drug” or “horse tranquilizer,” now sells more than one of the most notable 21st-century pharmaceuticals. This patent gives someone the motivation to fund FDA trials.

FDA 260
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

The selections feature topics ranging from how Wikipedia pages communicate drug efficacy information, to addressing pharmaceutical industry payments to physicians, to the frequency with which the Food and Drug Administration removes hazardous dietary supplements from the market. J Health Polit Policy Law. 2022 Jul 14:10041093.

article thumbnail

California Enters Insulin Manufacturing: Can We Expect to See a California Effect?

Bill of Health

Once approved by the FDA, CalRx insulin will be made available at $30 to all Californians who need it. Increased access to drug pricing data can inform innovation policy decisions on exclusivities, competition, and access for the pharmaceutical industry in general. Insulin is the first product the initiative will manufacture.

article thumbnail

Fluree, Vitality TechNet Partner to Enable Pharma Regulation & Drug Discovery

HIT Consultant

The pharmaceutical industry has long grappled with lengthy timelines and low success rates for new drugs and treatments. But efficient and credible data sharing can spur better processes with the potential to save lives, cut costs, and enable more collaboration across the pharmaceutical industry. years, with only a 7.9%